Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SERCA 2a gene therapy - Theragene Pharmaceuticals

Drug Profile

SERCA 2a gene therapy - Theragene Pharmaceuticals

Alternative Names: AAV1/SERCA2a; Congestive heart failure gene therapy; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy

Latest Information Update: 04 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Eiger BioPharmaceuticals, Inc.; Theragene Pharmaceuticals
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension; Renal failure
  • No development reported Heart failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 04 Feb 2020 No development reported - Phase-II for Heart failure in France, Sweden, United Kingdom, Hungary, Poland, Israel, Netherlands, Denmark, Belgium, Germany, Germany, USA (Intracoronary)
  • 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
  • 29 Jun 2017 Theragene Pharmaceuticals acquires Mydicar® (rAAV1-SERCA2a) from Eiger BioPharmaceuticals
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top